REGN

REGN: To Present At Piper Jaffray Health Care Conference @ 08:30 ET [delayed] - 12/03 - 07:57 AM ET

REGN: Conference call regarding Regeneron Announces Presentation at the 20th Annual Piper Jaffray Healthcare Conference @ 08:30 ET Today [delayed] - 12/03 - 07:20 AM ET

Regeneron Announces Presentation at the 20th Annual Piper Jaffray Healthcare Conference - 12/01 - 09:30 AM ET

REGN: To Present At Credit Suisse Healthcare Conference @ 10:00 ET [delayed] - 11/12 - 08:24 AM ET

Regeneron Announces Presentation at the Credit Suisse 2008 Healthcare Conference - 11/10 - 09:30 AM ET

Regeneron Pharmaceuticals Picks Up Volume, Drops Sharply - 11/05 - 12:14 PM ET

BRIEF-Regeneron reports Q3 results - 11/04 - 07:02 AM ET

Regeneron Reports Third Quarter 2008 Financial and Operating Results - 11/04 - 07:00 AM ET

Regeneron reports encouraging results from Phase II AMD trial - 09/29 - 10:10 AM ET

VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeting - 09/28 - 03:00 PM ET

REGN: To Present At UBS Global Life Sciences Conference @ 16:30 ET [delayed] - 09/23 - 02:53 PM ET

Regeneron Announces Presentation at the UBS Global Life Sciences Conference - 09/19 - 09:30 AM ET

Regeneron and Columbia University collaborate to discover monoclonal antibodies - 09/17 - 10:35 AM ET

Regeneron and Columbia University Enter Into a Strategic VelocImmune(R) Agreement to Discover Human Monoclonal Antibodies - 09/16 - 08:00 AM ET

Regeneron's ARCALYST(R) (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy - 09/03 - 06:00 AM ET

REGN: Conference call regarding Results from Phase 2 Study of ARCALYST(R) (rilonacept) in Gout Patients Initiating Urate-Lowering Therapy @ 08:30 ET Today [delayed] - 09/02 - 08:48 PM ET

Regeneron Announces Webcast Presentation of Results from Phase 2 Study of ARCALYST(R) (rilonacept) in Gout Patients Initiating Urate-Lowering Therapy - 09/02 - 06:45 PM ET

Regeneron reports encouraging data from Phase II AMD trial - 08/20 - 11:59 AM ET

Regeneron/Bayer report VEGF Trap-Eye improves vision in Phase II extension study - 08/19 - 07:41 AM ET

Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular Degeneration - 08/19 - 07:00 AM ET

Page 1 of 5     1  2   3   4   5      Previous  |  Next

<< Back to Stock Index